Krsnaa Diagnostics Q4 FY26 earnings call: Revenue & Margins
Q4 FY26 earnings call: what management said on revenue, margins and capex.
- Revenue
- ₹173Cr
- −1.1% YoY
- +8.8% QoQ
- Net profit
- ₹43Cr
- +104.8% YoY
- +168.8% QoQ
- Margin
- 33%
- +2 pp YoY
- +3 pp QoQ
Krsnaa Diagnost. Q4 FY26 key numbers
- Revenue
- Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed.
As stated in Krsnaa Diagnost.'s Q4 FY26 earnings call transcript · published 31 May 2026. Reported figures, not investment advice.
The short version
Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed. FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers.
From Krsnaa Diagnost.'s Q4 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed.
- Radiology revenue growth anticipated in FY '27, with 10 new MRI centers added in Q1 and 7 more in pipeline, totaling ~260 radiology centers by FY '27 end.
- Retail diagnostics is a strong growth driver; retail contribution grew to about 8% in FY '26 and is targeted to scale to 25-30% of total revenue over 3-5 years.
- Touchpoints in retail network are growing quarter-on-quarter, with 3,500+ collection points and 500+ franchises nationally.
- Organic like-to-like growth on existing PPP projects is around 13% annually.
2 more points from Krsnaa Diagnost.'s call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores.
- Total INR 500 crores capex planned for FY '27, combining Rajasthan (~INR 300 crores), MRI projects (~INR 150 crores), and smaller projects in Jharkhand and Ranchi.
- This INR 500 crores represents capitalization expected in FY '27, involving a mix of debt and internal accruals.
- MRI center expansion in Maharashtra includes adding around 10 new MRI centers in the coming quarter (part of a total of 17 centers).
- Additional small projects and PPP opportunities under implementation and selective new projects being pursued cautiously.
2 more points from Krsnaa Diagnost.'s call on capex
Create a free account to keep reading this call
Fundraising & Capital Structure
See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current pipeline includes a couple of PPP projects under implementation, with no major new orders announced yet.
- Radiology expansion is ongoing with around 10 MRI centers being added in the current quarter and 7 more planned in coming quarters (total 17).
- Expected pathology lab network to reach approximately 297 centers by Q2 FY '27, including Rajasthan additions.
- Rajasthan project is under implementation, with major installations expected to complete by Q2 FY '27.
- Growth is expected to be calibrated given current capex and project pipeline.
- Board and management are selective about new PPP projects, focusing on long-term value creation rather than aggressive bidding.
2 more points from Krsnaa Diagnost.'s call on order book
Create a free account to keep reading this call
What the Q4 FY26 call signalled
2 of 4 strong
Krsnaa Diagnost. — Quarterly revenue & net profit
Krsnaa Diagnost. Q4 FY26 results — key figures
| ₹ Cr | Q4 FY26 | Q4 FY25 | YoY | Q3 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 173 | 175 | -1.1% | 159 | +8.8% |
| Operating profit (EBITDA) | 57 | 53 | +7.5% | 48 | +18.8% |
| Operating margin | 33% | 31% | +2 pp | 30% | +3 pp |
| Profit before tax | 54 | 29 | +86.2% | 21 | +157.1% |
| Net profit (PAT) | 43 | 21 | +104.8% | 16 | +168.8% |
| EPS (₹) | 13.37 | 6.53 | +104.7% | 5.08 | +163.2% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Suven Life Sciences (Q4 FY26)
The provided pages of the investor presentation do not report any revenue, sales, or volume figures for the quarter. Key investor presentation takeaways from Su
- Invicta Diagnostic (Q4 FY26)
Invicta Diagnostic Limited is deploying IPO funds (INR 21 crores raised) primarily towards: . Key concall takeaways from Invicta Diagnostic's Q4 FY26 earnings…
- KMC Speciality (Q4 FY26)
Q4 FY’26 Revenue from Operations: INR 82.3 Cr, up 35.0% YoY from INR 60.9 Cr in Q4 FY’25 (Page 20) . Key concall takeaways from KMC Speciality Hospitals…
- Star Imaging (Q4 FY26)
Capex planned for FY27 is around INR 20 to 25 crores, mainly towards new centres and equipment. Key concall takeaways from Star Imaging's Q4 FY26 earnings call…
Potential multibaggers · Q2 FY27
This quarter's potential multibaggers
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Krsnaa Diagnost. Q4 FY26 results?
Rajasthan project revenue expected between INR 100-150 crores in FY '27, with full installation by Q2 FY '27 and conservative ramp-up assumed. FY '27 expected to see decent scale improvements and at least maintain EBITDA margins, with potential upside from multiple growth levers.
What is Krsnaa Diagnost. share price analysis?
Krsnaa Diagnost. currently shows a below-average growth signal. The stock trades at a P/E of 19.1 with a market cap of ₹1,866 Cr. Investors should review the full earnings analysis for detailed insights.
Is Krsnaa Diagnost. planning capital expenditure?
Rajasthan capital expenditure: Capitalization to happen from Q1 FY '27, around INR 200 crores.
Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
